However, it has to be pointed out that Caspase-4+ K-Ras -– (Fig. 3j, blue line; Fig. 3l, 14.8%) or Caspase-4+ cMyC- (Fig. 3g, blue line; Fig. 3i, 33.3%) NSCLC patients still had lower survival rate. This evidence concerns the gene KRAS and non-small cell lung carcinoma.